Alpha Teknova (TKNO) and Its Rivals Financial Survey

Alpha Teknova (NASDAQ:TKNO – Get Rating) is one of 39 publicly-traded companies in the “Diagnostic substances” industry, but how does it contrast to its peers? We will compare Alpha Teknova to related companies based on the strength of its valuation, institutional ownership, earnings, profitability, dividends, analyst recommendations and risk.

Analyst Recommendations

This is a summary of current recommendations for Alpha Teknova and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Teknova	0	0	4	0	3.00
Alpha Teknova Competitors	250	780	1245	40	2.46

Alpha Teknova currently has a consensus price target of $27.33, indicating a potential upside of 112.55%. As a group, “Diagnostic substances” companies have a potential upside of 94.81%. Given Alpha Teknova’s stronger consensus rating and higher probable upside, equities analysts plainly believe Alpha Teknova is more favorable than its peers.

Profitability

This table compares Alpha Teknova and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Teknova	-37.59%	-10.02%	-8.64%
Alpha Teknova Competitors	-2,882.38%	-1,237.22%	-26.09%

Earnings & Valuation

This table compares Alpha Teknova and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Teknova	$36.89 million	-$9.80 million	-13.26
Alpha Teknova Competitors	$409.34 million	$33.17 million	-89.42

Alpha Teknova’s peers have higher revenue and earnings than Alpha Teknova. Alpha Teknova is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

25.5% of Alpha Teknova shares are held by institutional investors. Comparatively, 53.3% of shares of all “Diagnostic substances” companies are held by institutional investors. 10.2% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alpha Teknova beats its peers on 7 of the 12 factors compared.

Alpha Teknova Company Profile (Get Rating)

Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.